What is Avisi?
Avisi Technologies operates at the intersection of advanced engineering and clinical ophthalmology. The company is dedicated to transforming the standard of care for ocular conditions through a robust portfolio of medical devices, most notably the VisiPlate aqueous shunt and the V-001 sustained intraocular drug-delivery platform. By focusing on high-precision solutions for glaucoma, Avisi has established a significant market presence, supported by a network of prestigious research institutions and accelerators. The company's strategic focus remains on delivering scalable, state-of-the-art treatments that improve patient outcomes while streamlining surgical procedures for mild to moderate glaucoma cases.
How much funding has Avisi raised?
Avisi has raised a total of $10.7M across 1 funding round:
Series A
$10.7M
Series A (2026): $10.7M with participation from OneOneFive, MedVenture Partners, Gemseki, and Golden Seeds
Key Investors in Avisi
Golden Seeds
A New York-based venture capital firm specializing in early-stage and growth capital investments, providing strategic support to high-potential startups.
MedVenture Partners
A Menlo Park-based firm focused on research and development, providing critical expertise and capital to advance medical technology innovation.
Gemseki
A specialized division of Shin Nippon Science Co., Ltd. that facilitates the global brokerage and licensing of drug discovery technologies and medical seeds.
What's next for Avisi?
With this major enterprise-level funding, Avisi is expected to prioritize the expansion of its clinical trial infrastructure and the refinement of its manufacturing processes. The strategic roadmap likely involves scaling the production of the VisiPlate-S drainage device to meet anticipated demand following cataract surgery integration. Furthermore, the company will likely utilize these resources to deepen its engagement with regulatory bodies and expand its intellectual property footprint. As Avisi moves deeper into its clinical-stage lifecycle, the focus will shift toward securing long-term commercial partnerships and validating the long-term efficacy of its drug-delivery platforms in broader patient populations, ensuring sustained growth in the competitive medical device landscape.
See full Avisi company page
